Physician profile
Bashir Ahmed
NPI 1659537827
$5,027.49
in general payments reported to CMS, 2019-2025
24 companies · $653 in 2025
The $653 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $218 · 2021: $992 · 2022: $1,109 · 2023: $915 · 2024: $1,013 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,581.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,272.75 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $679.56 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $668.03 | 2021-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $369.05 | 2020-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $319.50 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $298.37 | 2019-2025 | Trintellix |
| Allergan, INC. | $195.53 | 2019-2020 | |
| Tris Pharma INC | $168.84 | 2022-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $134.24 | 2022-2024 | Quviviq |
| Noven Therapeutics, LLC | $121.43 | 2023-2025 | Xelstrym, Secuado |
| Bausch Health US, LLC | $117.69 | 2020-2025 | Wellbutrin, Aplenzin |
| Axsome Therapeutics, INC. | $109.01 | 2022-2025 | Auvelity |
| Lundbeck LLC | $108.06 | 2022-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $95.47 | 2021-2023 | Qelbree |
| Almatica Pharma LLC | $89.45 | 2021-2023 | Loreev Xr, Venlafaxine, Citalopram |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $65.94 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $49.48 | 2025 | Lybalvi, Aristada |
| Jazz Pharmaceuticals INC. | $43.35 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $38.90 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $25.42 | 2024 | Uzedy |
| Adlon Therapeutics L.P. | $19.33 | 2020 | |
| Avion Pharmaceuticals | $13.85 | 2023 | Methylphenidate Hydrochloride |
| Shire North American Group INC | $12.24 | 2019 | |
| Eisai INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashir Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.